Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> Tunicamycin [11089-65-9]

Tunicamycin [11089-65-9]

Imprimir Imprimir
Please log in

Referência HY-A0098-2mg

Tamanho : 2mg

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits N-linked glycosylation and blocks GlcNAc phosphotransferase (GPT). Tunicamycin causes accumulation of unfolded proteins in cell endoplasmic reticulum (ER) and induces ER stress, and causes blocking of DNA synthesis and cell cycle arrest in G1 phase. Tunicamycin inhibits gram-positive bacteria, yeasts, fungi, and viruses and has anti-cancer activity[1][2][3].Tunicamycin increases exosome release in cervical cancer cells[4].

In Vitro

Tunicamycin (2 μg/mL; 24 hours; CD44+/CD24- and original MCF7 cells) treatment increases the spliced XBP-1, ATF6 nuclear translocation level and CHOP protein expression in CD44+/CD24- and original MCF7 cells[1].
Tunicamycin-induced ER stress suppresses CD44+/CD24- phenotype cell subpopulation and in vitro invasion and accelerates tumorosphore formation. Under effect of Tunicamycin, the results show that inhibited invasion, increased cell death, suppressed proliferation and reduced migration in the CD44+/CD24- and CD44+/CD24- rich MCF7 cell culture[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tunicamycin Related Antibodies

Western Blot Analysis

Cell Line: CD44+/CD24- and original MCF7 cells[1]
Concentration: 2 µg/mL
Incubation Time: 24 hours
Result: Increased level of spliced XBP-1, ATF6 nuclear translocation and CHOP protein expression are detected in CD44+/CD24- and original MCF7 cells.
In Vivo

Tunicamycin (0.1 mg/kg or 0.5 mg/kg) treatment dramatically suppresses tumor growth in the CD133+/- MHCC97L cells xenograft model (BALB/c (nu/nu) mice)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Masse moléculaire

844.94 (n=10)

Formule

C39H64N4O16
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C1NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](C(C[C@@H]3[C@H](O)[C@H](O)[C@@H](NC(/C=C/[(CH2) 8-11]C(C)C)=O)[C@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4NC(C)=O)O3)O)O2)C=C1)=O
Structure Classification
Initial Source

Streptomyces lysosuperficus
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 33.33 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 10 mg/mL (adjust pH to 12 with 1 M NaOH)

Ethanol : 1 mg/mL (ultrasonic and warming and heat to 60°C)

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2 mg/mL; Clear solution

    This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2 mg/mL; Clear solution

    This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT